Journal article
The SIGLEC14 null allele is associated with Mycobacterium tuberculosis- and BCG-induced clinical and immunologic outcomes
AD Graustein, DJ Horne, JJ Fong, F Schwarz, HC Mefford, GJ Peterson, RD Wells, M Musvosvi, M Shey, WA Hanekom, M Hatherill, TJ Scriba, NTT Thuong, NTH Mai, M Caws, ND Bang, SJ Dunstan, GE Thwaites, A Varki, T Angata Show all
Tuberculosis | CHURCHILL LIVINGSTONE | Published : 2017
Abstract
Humans exposed to Mycobacterium tuberculosis (Mtb) have variable susceptibility to tuberculosis (TB) and its outcomes. Siglec-5 and Siglec-14 are members of the sialic-acid binding lectin family that regulate immune responses to pathogens through inhibitory (Siglec-5) and activating (Siglec-14) domains. The SIGLEC14 coding sequence is deleted in a high proportion of individuals, placing a SIGLEC5-like gene under the expression of the SIGLEC14 promoter (the SIGLEC14 null allele) and causing expression of a Siglec-5 like protein in monocytes and macrophages. We hypothesized that the SIGLEC14 null allele was associated with Mtb replication in monocytes, T-cell responses to the BCG vaccine, and ..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
We would like to thank the participants in the study. We would also like to thank the immunology and clinical teams at the SATVI research site in Worchester and the Hospital for Tropical Diseases and Pham Ngoc Thac Hospital in Vietnam for obtaining informed consent and collecting and processing blood from the study participants. This research was supported by NIH 5T32HL007287 (ADG), NIH K24 AI089794 (TRH), NIH NO1-AI-70022 (Tuberculosis Research Unit) (TRH, WAH), the Burroughs Wellcome Foundation 1008461 (TRH), and the Dana Foundation (TRH and WAH).